Christopher Rovaldi
2022
In 2022, Christopher Rovaldi earned a total compensation of $4.2M as Chief Operating Officer at Keros Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $235,000 |
|---|---|
| Option Awards | $3,538,605 |
| Salary | $435,352 |
| Other | $38,397 |
| Total | $4,247,354 |
Rovaldi received $3.5M in option awards, accounting for 83% of the total pay in 2022.
Rovaldi also received $235K in non-equity incentive plan, $435.4K in salary and $38.4K in other compensation.
Rankings
In 2022, Christopher Rovaldi's compensation ranked 801st out of 5,625 executives tracked by ExecPay. In other words, Rovaldi earned more than 85.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 801 out of 5,625 | 86th |
Division Manufacturing | 362 out of 3,053 | 88th |
Major group Chemicals And Allied Products | 120 out of 1,380 | 91st |
Industry group Drugs | 107 out of 1,281 | 92nd |
Industry Pharmaceutical Preparations | 79 out of 927 | 92nd |
Source: SEC filing on April 24, 2023.
Rovaldi's colleagues
We found two more compensation records of executives who worked with Christopher Rovaldi at Keros Therapeutics in 2022.